The idea seemed captivating: contact lens in the eye should also measure the glucose levels of diabetic patients – because in the crying there are blood sugar deposits. Novartis and Google (or, more precisely, the subsidiary of Novartis, Alcon and Verily's Alphabet Healthcare division) met four years ago to bring together their developing know-how.
Obviously, the results were disappointing. as Brian Otis, Said the technical director of Verily, the project will be suspended. "We are at a point where together with Alcon we decided to stop working on the glucose sensitive lens," Otis wrote on Verily's blog.
Clinical trials have shown that there are very few consistent relationships between blood glucose levels crying and give the blood values. It has proven to be too complex to safely measure glucose concentrations in the eye. The "requirements of a medical device" could not be met in this situation, Brian Otis,
Both sides emphasize, however, that this does not mean the complete abolition of Verily and Alcon's teamwork. We continue to work on the development of an adaptive model contact lens for patients with long-term vision and an intelligent intraocular lens to improve vision after cataract surgery.
"We are looking forward to the next phase of development of our other two Smart Lens programs with Verily," Novartis said on request. "We apply our technical knowledge and significant achievements to common eye diseases." (RAP MUSIC)